{"result": {"id": "6c692146-1665-46e0-a17a-b202c4d0fba6", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>EPITHELIAL SODIUM CHANNEL 1Β SUBUNIT<|>PERSON<|>Protein encoded by SCNN1B gene, associated with Liddle syndrome)\n##\n(\"entity\"<|>EPITHELIAL SODIUM CHANNEL 1Γ SUBUNIT<|>PERSON<|>Protein encoded by SCNN1G gene, associated with Liddle syndrome)\n##\n(\"entity\"<|>LYSINE-DEFICIENT PROTEIN KINASE 1<|>PERSON<|>Protein encoded by WNK1 gene, associated with Gordon syndrome)\n##\n(\"entity\"<|>LYSINE-DEFICIENT PROTEIN KINASE 4<|>PERSON<|>Protein encoded by WNK4 gene, associated with Gordon syndrome)\n##\n(\"entity\"<|>KELCH-LIKE FAMILY MEMBER 3<|>PERSON<|>Protein encoded by KLHL3 gene, associated with Gordon syndrome)\n##\n(\"entity\"<|>CULLIN3 PROTEIN<|>PERSON<|>Protein encoded by CUL3 gene, associated with Gordon syndrome)\n##\n(\"entity\"<|>11-Β-HYDROXYSTEROID DEHYDROGENASE 2<|>PERSON<|>Protein encoded by HSD11B2 gene, associated with apparent mineralocorticoid excess)\n##\n(\"entity\"<|>CYTOCHROME P450 FAMILY 17 SUBFAMILY A MEMBER 1<|>PERSON<|>Protein encoded by CYP17A1 gene, associated with 17α-hydroxylase deficiency)\n##\n(\"entity\"<|>CYTOCHROME P450 FAMILY 11 SUBFAMILY B MEMBER 1<|>PERSON<|>Protein encoded by CYP11B1 gene, associated with 11β-hydroxylase deficiency)\n##\n(\"entity\"<|>CYTOCHROME P450 FAMILY 11 SUBFAMILY B MEMBER 2<|>PERSON<|>Protein encoded by CYP11B2 gene, associated with familial hyperaldosteronism type I)\n##\n(\"entity\"<|>CHLORIDE VOLTAGE-GATED CHANNEL 2<|>PERSON<|>Protein encoded by CLCN2 gene, associated with familial hyperaldosteronism type II)\n##\n(\"entity\"<|>INWARDLY RECTIFYING POTASSIUM CHANNEL SUBFAMILY J MEMBER 5<|>PERSON<|>Protein encoded by KCNJ5 gene, associated with familial hyperaldosteronism type III)\n##\n(\"entity\"<|>CALCIUM VOLTAGE-GATED CHANNEL SUBUNIT ALPHA1 H<|>PERSON<|>Protein encoded by CACNA1H gene, associated with familial hyperaldosteronism type IV)\n##\n(\"entity\"<|>NUCLEAR RECEPTOR SUBFAMILY 3 GROUP C MEMBER 1<|>PERSON<|>Protein encoded by NR3C1 gene, associated with generalized glucocorticoid resistance)\n##\n(\"relationship\"<|>EPITHELIAL SODIUM CHANNEL 1Β SUBUNIT<|>SCNN1B<|>The epithelial sodium channel 1β subunit is encoded by SCNN1B gene<|>9)\n##\n(\"relationship\"<|>EPITHELIAL SODIUM CHANNEL 1Γ SUBUNIT<|>SCNN1G<|>The epithelial sodium channel 1γ subunit is encoded by SCNN1G gene<|>9)\n##\n(\"relationship\"<|>LYSINE-DEFICIENT PROTEIN KINASE 1<|>WNK1<|>Lysine-deficient protein kinase 1 is encoded by WNK1 gene<|>9)\n##\n(\"relationship\"<|>LYSINE-DEFICIENT PROTEIN KINASE 4<|>WNK4<|>Lysine-deficient protein kinase 4 is encoded by WNK4 gene<|>9)\n##\n(\"relationship\"<|>KELCH-LIKE FAMILY MEMBER 3<|>KLHL3<|>Kelch-like family member 3 is encoded by KLHL3 gene<|>9)\n##\n(\"relationship\"<|>CULLIN3 PROTEIN<|>CUL3<|>Cullin3 protein is encoded by CUL3 gene<|>9)\n##\n(\"relationship\"<|>11-Β-HYDROXYSTEROID DEHYDROGENASE 2<|>HSD11B2<|>11-β-hydroxysteroid dehydrogenase 2 is encoded by HSD11B2 gene<|>9)\n##\n(\"relationship\"<|>CYTOCHROME P450 FAMILY 17 SUBFAMILY A MEMBER 1<|>CYP17A1<|>Cytochrome P450 family 17 subfamily A member 1 is encoded by CYP17A1 gene<|>9)\n##\n(\"relationship\"<|>CYTOCHROME P450 FAMILY 11 SUBFAMILY B MEMBER 1<|>CYP11B1<|>Cytochrome P450 family 11 subfamily B member 1 is encoded by CYP11B1 gene<|>9)\n##\n(\"relationship\"<|>CYTOCHROME P450 FAMILY 11 SUBFAMILY B MEMBER 2<|>CYP11B2<|>Cytochrome P450 family 11 subfamily B member 2 is encoded by CYP11B2 gene<|>9)\n##\n(\"relationship\"<|>CHLORIDE VOLTAGE-GATED CHANNEL 2<|>CLCN2<|>Chloride voltage-gated channel 2 is encoded by CLCN2 gene<|>9)\n##\n(\"relationship\"<|>INWARDLY RECTIFYING POTASSIUM CHANNEL SUBFAMILY J MEMBER 5<|>KCNJ5<|>Inwardly rectifying potassium channel subfamily J member 5 is encoded by KCNJ5 gene<|>9)\n##\n(\"relationship\"<|>CALCIUM VOLTAGE-GATED CHANNEL SUBUNIT ALPHA1 H<|>CACNA1H<|>Calcium voltage-gated channel subunit alpha1 H is encoded by CACNA1H gene<|>9)\n##\n(\"relationship\"<|>NUCLEAR RECEPTOR SUBFAMILY 3 GROUP C MEMBER 1<|>NR3C1<|>Nuclear receptor subfamily 3 group C member 1 is encoded by NR3C1 gene<|>9)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751558913, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 1464, "prompt_tokens": 5626, "total_tokens": 7090, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 5568}, "prompt_cache_hit_tokens": 5568, "prompt_cache_miss_tokens": 58}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 压及其致病基因、临床特征\n\n疾病类型\t致病基因\t典型临床特征\nLiddle综合征\tSCNN1B、SCNN1G\t早发高血压 ,低血钾 ,PRA↓ ,PAC↓ ,阿米洛利或氨苯蝶啶治疗有效\nGordon综合征\tWNK1、WNK4、KLHL3、CUL3\t早发高血压 ,高血钾 ,高血氯 ,代谢性酸中毒 ,PRA↓ ,PAC↓/- ,部分 合并发育障碍\n表观盐皮质激素增多症\tHSD11B2\t轻型可仅高血压 ,重型合并发育障碍 ,PRA↓ ,PAC↓\n17α-羟化酶缺陷症\tCYP17A1\t第二性征发育不良 ,原发性闭经 ,早发高血压 ,低血钾 ,PRA↓ ,PAC↓\n11β-羟化酶缺乏症\tCYP11B1\t男性性早熟和女性假两性畸形 ,早发高血压 ,低血钾 , PRA↓ ,PAC↓\n　家族性醛固酮增多症Ⅰ型(糖皮   质激素可治疗性醛固酮增多症)\tCYP11B2/CYP11B1嵌合变异\t早发高血压 ,低血钾 ,PRA↓ ,PAC↑ ,糖皮质激素治疗有效\n家族性醛固酮增多症Ⅱ型\tCLCN2\t高血压 ,低血钾 ,醛固酮瘤或双侧肾上腺增生 ,PRA↓ ,PAC↑\n家族性醛固酮增多症Ⅲ型\tKCNJ5\t高血压 ,低血钾 ,多见双侧肾上腺增生 ,PRA↓ ,PAC↑\n家族性醛固酮增多症Ⅳ型\tCACNA1H\t高血压 ,低血钾 ,多见醛固酮瘤 ,PRA↓ ,PAC↑\n全身性糖皮质激素抵抗 (Chrousos综合征)\tNR3C1\t血浆皮质醇显著升高 ,雄激素增多 ,高血压 ,低钾血症 ,PRA↓ ,PAC↓\n嗜铬细胞瘤/副神经节瘤\tVHL、RET、NF1、SDHB、SDHC、SDHD、MAX、 TMEM127、EPAS1、SDHA、FH、SDHAF2\t儿茶酚胺高分泌(血压升高和代谢性改变) 表现 ,及肿瘤占位相关 症状\n　　注 :SCNN1B为上皮钠通道 1β亚单位;SCNN1G为上皮钠通道 1γ亚单位;WNK1为赖氨酸缺乏蛋白激酶 1;WNK4为赖氨酸缺乏蛋白激酶 4;  KLHL3为 kelch蛋白样家族成员 3;CUL3为 cullin3蛋白;HSD11B2为 11-β-羟基类固醇脱氢酶 2;CYP17A1为细胞色素 P450第 17家族亚家族 A 成员 1;CYP11B1为细胞色素 P450第 11家族亚家族 B成员 1;CYP11B2为细胞色素 P450第 11家族亚家族 B成员 2;CLCN2为氯离子电压门控通  道 2;KCNJ5为内向整流型钾离子通道亚家族 J成员 5;CACNA1H为钙离子电压门控通道 α1H亚单位;NR3C\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>LIDDLE SYNDROME<|>EVENT<|>A genetic disorder caused by mutations in SCNN1B and SCNN1G genes, characterized by early-onset hypertension, hypokalemia, low PRA and PAC, and responsiveness to amiloride or triamterene treatment)\n##\n(\"entity\"<|>SCNN1B<|>PERSON<|>Gene encoding the epithelial sodium channel 1β subunit, associated with Liddle syndrome)\n##\n(\"entity\"<|>SCNN1G<|>PERSON<|>Gene encoding the epithelial sodium channel 1γ subunit, associated with Liddle syndrome)\n##\n(\"entity\"<|>GORDON SYNDROME<|>EVENT<|>A genetic disorder caused by mutations in WNK1, WNK4, KLHL3, and CUL3 genes, characterized by early-onset hypertension, hyperkalemia, hyperchloremia, metabolic acidosis, low PRA and PAC, and possible developmental disorders)\n##\n(\"entity\"<|>WNK1<|>PERSON<|>Gene encoding lysine-deficient protein kinase 1, associated with Gordon syndrome)\n##\n(\"entity\"<|>WNK4<|>PERSON<|>Gene encoding lysine-deficient protein kinase 4, associated with Gordon syndrome)\n##\n(\"entity\"<|>KLHL3<|>PERSON<|>Gene encoding kelch-like family member 3, associated with Gordon syndrome)\n##\n(\"entity\"<|>CUL3<|>PERSON<|>Gene encoding cullin3 protein, associated with Gordon syndrome)\n##\n(\"entity\"<|>APPEARENT MINERALOCORTICOID EXCESS<|>EVENT<|>A genetic disorder caused by mutations in HSD11B2 gene, characterized by hypertension, possible developmental disorders, low PRA and PAC)\n##\n(\"entity\"<|>HSD11B2<|>PERSON<|>Gene encoding 11-β-hydroxysteroid dehydrogenase 2, associated with apparent mineralocorticoid excess)\n##\n(\"entity\"<|>17α-HYDROXYLASE DEFICIENCY<|>EVENT<|>A genetic disorder caused by mutations in CYP17A1 gene, characterized by poor secondary sexual characteristics, primary amenorrhea, early-onset hypertension, hypokalemia, low PRA and PAC)\n##\n(\"entity\"<|>CYP17A1<|>PERSON<|>Gene encoding cytochrome P450 family 17 subfamily A member 1, associated with 17α-hydroxylase deficiency)\n##\n(\"entity\"<|>11β-HYDROXYLASE DEFICIENCY<|>EVENT<|>A genetic disorder caused by mutations in CYP11B1 gene, characterized by male precocious puberty and female pseudohermaphroditism, early-onset hypertension, hypokalemia, low PRA and PAC)\n##\n(\"entity\"<|>CYP11B1<|>PERSON<|>Gene encoding cytochrome P450 family 11 subfamily B member 1, associated with 11β-hydroxylase deficiency)\n##\n(\"entity\"<|>FAMILIAL HYPERALDOSTERONISM TYPE I<|>EVENT<|>A genetic disorder caused by chimeric variants of CYP11B2/CYP11B1 genes, characterized by early-onset hypertension, hypokalemia, low PRA, high PAC, and responsiveness to glucocorticoid treatment)\n##\n(\"entity\"<|>CYP11B2<|>PERSON<|>Gene encoding cytochrome P450 family 11 subfamily B member 2, associated with familial hyperaldosteronism type I)\n##\n(\"entity\"<|>FAMILIAL HYPERALDOSTERONISM TYPE II<|>EVENT<|>A genetic disorder caused by mutations in CLCN2 gene, characterized by hypertension, hypokalemia, aldosterone-producing adenoma or bilateral adrenal hyperplasia, low PRA and high PAC)\n##\n(\"entity\"<|>CLCN2<|>PERSON<|>Gene encoding chloride voltage-gated channel 2, associated with familial hyperaldosteronism type II)\n##\n(\"entity\"<|>FAMILIAL HYPERALDOSTERONISM TYPE III<|>EVENT<|>A genetic disorder caused by mutations in KCNJ5 gene, characterized by hypertension, hypokalemia, bilateral adrenal hyperplasia, low PRA and high PAC)\n##\n(\"entity\"<|>KCNJ5<|>PERSON<|>Gene encoding inwardly rectifying potassium channel subfamily J member 5, associated with familial hyperaldosteronism type III)\n##\n(\"entity\"<|>FAMILIAL HYPERALDOSTERONISM TYPE IV<|>EVENT<|>A genetic disorder caused by mutations in CACNA1H gene, characterized by hypertension, hypokalemia, aldosterone-producing adenoma, low PRA and high PAC)\n##\n(\"entity\"<|>CACNA1H<|>PERSON<|>Gene encoding calcium voltage-gated channel subunit alpha1 H, associated with familial hyperaldosteronism type IV)\n##\n(\"entity\"<|>GENERALIZED GLUCOCORTICOID RESISTANCE (CHROUSOS SYNDROME)<|>EVENT<|>A genetic disorder caused by mutations in NR3C1 gene, characterized by significantly elevated plasma cortisol, increased androgens, hypertension, hypokalemia, low PRA and PAC)\n##\n(\"entity\"<|>NR3C1<|>PERSON<|>Gene encoding nuclear receptor subfamily 3 group C member 1, associated with generalized glucocorticoid resistance)\n##\n(\"entity\"<|>PHEOCHROMOCYTOMA/PARAGANGLIOMA<|>EVENT<|>A genetic disorder caused by mutations in VHL, RET, NF1, SDHB, SDHC, SDHD, MAX, TMEM127, EPAS1, SDHA, FH, SDHAF2 genes, characterized by catecholamine hypersecretion and tumor-related symptoms)\n##\n(\"entity\"<|>VHL<|>PERSON<|>Gene associated with pheochromocytoma/paraganglioma)\n##\n(\"entity\"<|>RET<|>PERSON<|>Gene associated with pheochromocytoma/paraganglioma)\n##\n(\"entity\"<|>NF1<|>PERSON<|>Gene associated with pheochromocytoma/paraganglioma)\n##\n(\"entity\"<|>SDHB<|>PERSON<|>Gene associated with pheochromocytoma/paraganglioma)\n##\n(\"entity\"<|>SDHC<|>PERSON<|>Gene associated with pheochromocytoma/paraganglioma)\n##\n(\"entity\"<|>SDHD<|>PERSON<|>Gene associated with pheochromocytoma/paraganglioma)\n##\n(\"entity\"<|>MAX<|>PERSON<|>Gene associated with pheochromocytoma/paraganglioma)\n##\n(\"entity\"<|>TMEM127<|>PERSON<|>Gene associated with pheochromocytoma/paraganglioma)\n##\n(\"entity\"<|>EPAS1<|>PERSON<|>Gene associated with pheochromocytoma/paraganglioma)\n##\n(\"entity\"<|>SDHA<|>PERSON<|>Gene associated with pheochromocytoma/paraganglioma)\n##\n(\"entity\"<|>FH<|>PERSON<|>Gene associated with pheochromocytoma/paraganglioma)\n##\n(\"entity\"<|>SDHAF2<|>PERSON<|>Gene associated with pheochromocytoma/paraganglioma)\n##\n(\"relationship\"<|>LIDDLE SYNDROME<|>SCNN1B<|>SCNN1B gene is one of the causative genes for Liddle syndrome<|>9)\n##\n(\"relationship\"<|>LIDDLE SYNDROME<|>SCNN1G<|>SCNN1G gene is one of the causative genes for Liddle syndrome<|>9)\n##\n(\"relationship\"<|>GORDON SYNDROME<|>WNK1<|>WNK1 gene is one of the causative genes for Gordon syndrome<|>9)\n##\n(\"relationship\"<|>GORDON SYNDROME<|>WNK4<|>WNK4 gene is one of the causative genes for Gordon syndrome<|>9)\n##\n(\"relationship\"<|>GORDON SYNDROME<|>KLHL3<|>KLHL3 gene is one of the causative genes for Gordon syndrome<|>9)\n##\n(\"relationship\"<|>GORDON SYNDROME<|>CUL3<|>CUL3 gene is one of the causative genes for Gordon syndrome<|>9)\n##\n(\"relationship\"<|>APPEARANT MINERALOCORTICOID EXCESS<|>HSD11B2<|>HSD11B2 gene is the causative gene for apparent mineralocorticoid excess<|>9)\n##\n(\"relationship\"<|>17α-HYDROXYLASE DEFICIENCY<|>CYP17A1<|>CYP17A1 gene is the causative gene for 17α-hydroxylase deficiency<|>9)\n##\n(\"relationship\"<|>11β-HYDROXYLASE DEFICIENCY<|>CYP11B1<|>CYP11B1 gene is the causative gene for 11β-hydroxylase deficiency<|>9)\n##\n(\"relationship\"<|>FAMILIAL HYPERALDOSTERONISM TYPE I<|>CYP11B2<|>CYP11B2 gene is one of the causative genes for familial hyperaldosteronism type I<|>9)\n##\n(\"relationship\"<|>FAMILIAL HYPERALDOSTERONISM TYPE I<|>CYP11B1<|>CYP11B1 gene is one of the causative genes for familial hyperaldosteronism type I<|>9)\n##\n(\"relationship\"<|>FAMILIAL HYPERALDOSTERONISM TYPE II<|>CLCN2<|>CLCN2 gene is the causative gene for familial hyperaldosteronism type II<|>9)\n##\n(\"relationship\"<|>FAMILIAL HYPERALDOSTERONISM TYPE III<|>KCNJ5<|>KCNJ5 gene is the causative gene for familial hyperaldosteronism type III<|>9)\n##\n(\"relationship\"<|>FAMILIAL HYPERALDOSTERONISM TYPE IV<|>CACNA1H<|>CACNA1H gene is the causative gene for familial hyperaldosteronism type IV<|>9)\n##\n(\"relationship\"<|>GENERALIZED GLUCOCORTICOID RESISTANCE (CHROUSOS SYNDROME)<|>NR3C1<|>NR3C1 gene is the causative gene for generalized glucocorticoid resistance<|>9)\n##\n(\"relationship\"<|>PHEOCHROMOCYTOMA/PARAGANGLIOMA<|>VHL<|>VHL gene is one of the causative genes for pheochromocytoma/paraganglioma<|>9)\n##\n(\"relationship\"<|>PHEOCHROMOCYTOMA/PARAGANGLIOMA<|>RET<|>RET gene is one of the causative genes for pheochromocytoma/paraganglioma<|>9)\n##\n(\"relationship\"<|>PHEOCHROMOCYTOMA/PARAGANGLIOMA<|>NF1<|>NF1 gene is one of the causative genes for pheochromocytoma/paraganglioma<|>9)\n##\n(\"relationship\"<|>PHEOCHROMOCYTOMA/PARAGANGLIOMA<|>SDHB<|>SDHB gene is one of the causative genes for pheochromocytoma/paraganglioma<|>9)\n##\n(\"relationship\"<|>PHEOCHROMOCYTOMA/PARAGANGLIOMA<|>SDHC<|>SDHC gene is one of the causative genes for pheochromocytoma/paraganglioma<|>9)\n##\n(\"relationship\"<|>PHEOCHROMOCYTOMA/PARAGANGLIOMA<|>SDHD<|>SDHD gene is one of the causative genes for pheochromocytoma/paraganglioma<|>9)\n##\n(\"relationship\"<|>PHEOCHROMOCYTOMA/PARAGANGLIOMA<|>MAX<|>MAX gene is one of the causative genes for pheochromocytoma/paraganglioma<|>9)\n##\n(\"relationship\"<|>PHEOCHROMOCYTOMA/PARAGANGLIOMA<|>TMEM127<|>TMEM127 gene is one of the causative genes for pheochromocytoma/paraganglioma<|>9)\n##\n(\"relationship\"<|>PHEOCHROMOCYTOMA/PARAGANGLIOMA<|>EPAS1<|>EPAS1 gene is one of the causative genes for pheochromocytoma/paraganglioma<|>9)\n##\n(\"relationship\"<|>PHEOCHROMOCYTOMA/PARAGANGLIOMA<|>SDHA<|>SDHA gene is one of the causative genes for pheochromocytoma/paraganglioma<|>9)\n##\n(\"relationship\"<|>PHEOCHROMOCYTOMA/PARAGANGLIOMA<|>FH<|>FH gene is one of the causative genes for pheochromocytoma/paraganglioma<|>9)\n##\n(\"relationship\"<|>PHEOCHROMOCYTOMA/PARAGANGLIOMA<|>SDHAF2<|>SDHAF2 gene is one of the causative genes for pheochromocytoma/paraganglioma<|>9)\n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_b45c18add8f3653cb6e2ead62dcd9800bae4077daf2c0206dee7c8d9e78150f3_v2"}